AstraZeneca Pharma India Limited has announced strategic senior management appointments to strengthen its oncology and market access capabilities. The pharmaceutical company disclosed these appointments in a regulatory filing dated March 31, 2026, pursuant to SEBI Listing Regulations.

Key Leadership Appointments

The company's Board of Directors, acting on recommendations from the Nomination and Remuneration Committee, has made two significant appointments effective April 1, 2026:

Both positions are classified as Senior Management Personnel roles under SEBI Listing Regulations and involve full-time employment terms.

Dr. Shashank Srinivasan's Profile

Dr. Srinivasan brings extensive clinical and industry expertise to his new role. As a clinical oncologist and alumnus of Tata Memorial Hospital (TMH), Mumbai, he previously served as a consultant in the GI Cancers Disease Management Group within the Division of Radiation Oncology. He holds a DNB in Radiation Oncology from Max Super Speciality Hospital, Vaishali.

His industry experience includes:

• Pfizer: Served as medical lead for the lung cancer portfolio, leading initiatives in the ALK+ NSCLC therapy area
• AstraZeneca: Previously held the position of Therapy Area Lead for GI and Lung Cancers
• Current Role: Serving as Interim Medical Director for Oncology at AstraZeneca India

Dr. Srinivasan has demonstrated expertise in establishing scientific leadership through industry partnerships, evidence generation, and precision care advancement.

Mr. Venkat Natarajan's Career Progression

Mr. Natarajan's promotion recognizes his contributions since joining the company in January 2024 as Market Access Lead. His achievements at AstraZeneca include:

• Building and strengthening the Market Access function
• Driving strategic access initiatives and expanding patient support programs
• Advancing state-level access models and pricing initiatives
• Strengthening governance of patient services and exploring private insurance partnerships

Professional Background

His expertise spans government, insurance, and self-pay segments, with experience in developing innovative affordability solutions including differential pricing and patient support programs across Asia and Eastern Europe markets.

Strategic Significance

These appointments reflect AstraZeneca Pharma India's focus on strengthening its oncology portfolio and market access capabilities. Both executives bring proven track records in their respective domains, with Dr. Srinivasan's clinical and medical affairs expertise complementing Mr. Natarajan's market access and patient affordability experience.

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI Listing Regulations, providing detailed profiles and appointment terms to stock exchanges BSE Limited and National Stock Exchange of India Limited.

AstraZeneca Pharma India Limited has successfully concluded its postal ballot process and declared the voting results for material related party transactions. The company announced on March 31, 2026, that both ordinary resolutions seeking approval for transactions with related entities have been passed by the requisite majority of non-related members.

Postal Ballot Overview

The postal ballot was conducted with a record date of February 20, 2026, covering 29,857 total shareholders on record. The voting process was entirely electronic, conducted through the National Securities Depository Limited (NSDL) platform from February 28, 2026, to March 29, 2026.

Resolution Results

Both resolutions related to material related party transactions received strong support from non-related shareholders. The first resolution for transactions with AstraZeneca UK Limited and the second for transactions with AstraZeneca AB, Sweden both achieved similar voting patterns.

Resolution 1: AstraZeneca UK Limited Transactions

Resolution 2: AstraZeneca AB Sweden Transactions

Voting Participation and Process

A total of 297 members participated in the electronic voting process. The promoter and promoter group, holding 18,750,000 shares, abstained from voting as they were interested parties in both resolutions. The voting process was supervised by Mr. Vijayakrishna K.T, a practicing Company Secretary, who served as the scrutinizer.

The postal ballot notice was distributed electronically in compliance with MCA circulars, eliminating the need for physical ballot forms. Invalid votes were recorded across categories, with 13,850 invalid votes from public institutions and 2,141 from public non-institutions for both resolutions.

Regulatory Compliance

The postal ballot was conducted in accordance with Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The voting results and scrutinizer's report have been made available on the company's website and NSDL's e-voting platform. The company has informed both BSE Limited and National Stock Exchange of India Limited about the successful passage of both resolutions, ensuring full regulatory compliance for the material related party transactions.